New Zealand markets close in 59 minutes

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4350+0.0300 (+2.14%)
At close: 04:00PM EDT
1.4415 +0.01 (+0.45%)
After hours: 05:35PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 77.07M
Enterprise value 6.28M
Trailing P/E 3.33
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.78
Price/book (mrq)0.72
Enterprise value/revenue 0.06
Enterprise value/EBITDA 0.24

Trading information

Stock price history

Beta (5Y monthly) 0.57
52-week change 3-17.05%
S&P500 52-week change 325.01%
52-week high 31.9950
52-week low 30.9900
50-day moving average 31.6335
200-day moving average 31.3975

Share statistics

Avg vol (3-month) 3323.41k
Avg vol (10-day) 3222.75k
Shares outstanding 553.89M
Implied shares outstanding 653.89M
Float 839.8M
% held by insiders 120.37%
% held by institutions 126.08%
Shares short (28 Mar 2024) 4653.82k
Short ratio (28 Mar 2024) 41.3
Short % of float (28 Mar 2024) 41.47%
Short % of shares outstanding (28 Mar 2024) 41.21%
Shares short (prior month 29 Feb 2024) 4564k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 21.98%
Operating margin (ttm)68.73%

Management effectiveness

Return on assets (ttm)10.90%
Return on equity (ttm)24.95%

Income statement

Revenue (ttm)103.78M
Revenue per share (ttm)1.97
Quarterly revenue growth (yoy)55.00%
Gross profit (ttm)N/A
Net income avi to common (ttm)22.81M
Diluted EPS (ttm)0.4300
Quarterly earnings growth (yoy)91.20%

Balance sheet

Total cash (mrq)76.33M
Total cash per share (mrq)1.42
Total debt (mrq)5.54M
Total debt/equity (mrq)5.19%
Current ratio (mrq)3.53
Book value per share (mrq)2.02

Cash flow statement

Operating cash flow (ttm)-32.99M
Levered free cash flow (ttm)-9.9M